Acute Porphyria Drug Database

A02BA53 - Famotidine, Combinations
Propably not porphyrinogenic
PNP

Rationale
Famotidine: Partly unmetabolized. No clinical observations pointing to CYP inducing properties. Combined with two inorganic salts without CYP intarective properties
Chemical description
Famotidine: Used in ventricular hyperacidity (H2-receptor antagonist). About 70% excreted in urine in unmetabolized form. Partly metabolized in the liver to inactive sulfoxide metabolite. Impaired liver function does not seem to change the kinetics. Famotidine: South African list: use with care. French list: avoid
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes A02B / A02BA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙